3 results
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm
EDP-235’sin vitro pharmacology and molecular mechanism of action at the American Society for Biochemistry and Molecular Biology 2022 Annual Meeting
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
22 Nov 21
Results of Operations and Financial Condition
4:05pm
Inhibitor EDP-235
oPresented preclinical data during the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)–World
- Prev
- 1
- Next